Characteristics of the Anti-HCV Positive Leukemia Patients
| Patient . | Sex/Age (yr) . | Estimated Duration of Infection (yr) . | ALT* (U/L) . | HCV RNA (×106 eq/mL) . | Piecemeal Necrosis (0-10) . | Biopsy Data† . | Portal Inflammation (0-4) . | Fibrosis (0-4) . | Knodell Score (0-22) . |
|---|---|---|---|---|---|---|---|---|---|
| Intralobular Inflammation Necrosis (0-4) . | |||||||||
| 1. TC | M/50 | 10 | 290 | .28 | |||||
| 2. EK | M/50 | 16 | 52 | 24.4 | 1 | 1 | 3 | 1 | 6 |
| 3. SS | F/24 | 4 | 43 | 3.6 | 1 | 1 | 3 | 0 | 5 |
| 4. WF‡ | M/47 | 4 | 119 | 1.04 | 1 | 1 | 3 | 1 | 6 |
| 5. JS | M/50 | 11 | 234 | 4.55 | 3 | 3 | 3 | 3 | 12 |
| 6. DP‡ | F/37 | 14 | 131 | 40.5 | 6 | 1 | 3 | 3 | 13 |
| 7. AS | F/22 | 9 | 75 | 1.08 | — | — | — | — | — |
| 8. NH | M/7 | 4 | 44 | 1.47 | — | — | — | — | — |
| 9. DM | M/39 | 9 | 78 | 15.62-153 | 1 | 1 | 4 | 4 | 10 |
| Mean ± SD | 36.2 ± 15.4 | 9.0 ± 4.4 | 118.4 | 10.3 | 2.2 | 1.3 | 3.2 | 2.0 | 8.7 |
| Range | 7-50 | 4-16 | 43-290 | .28-40.5 | 1-6 | 1-3 | 3-4 | 0-4 | 5-13 |
| Patient . | Sex/Age (yr) . | Estimated Duration of Infection (yr) . | ALT* (U/L) . | HCV RNA (×106 eq/mL) . | Piecemeal Necrosis (0-10) . | Biopsy Data† . | Portal Inflammation (0-4) . | Fibrosis (0-4) . | Knodell Score (0-22) . |
|---|---|---|---|---|---|---|---|---|---|
| Intralobular Inflammation Necrosis (0-4) . | |||||||||
| 1. TC | M/50 | 10 | 290 | .28 | |||||
| 2. EK | M/50 | 16 | 52 | 24.4 | 1 | 1 | 3 | 1 | 6 |
| 3. SS | F/24 | 4 | 43 | 3.6 | 1 | 1 | 3 | 0 | 5 |
| 4. WF‡ | M/47 | 4 | 119 | 1.04 | 1 | 1 | 3 | 1 | 6 |
| 5. JS | M/50 | 11 | 234 | 4.55 | 3 | 3 | 3 | 3 | 12 |
| 6. DP‡ | F/37 | 14 | 131 | 40.5 | 6 | 1 | 3 | 3 | 13 |
| 7. AS | F/22 | 9 | 75 | 1.08 | — | — | — | — | — |
| 8. NH | M/7 | 4 | 44 | 1.47 | — | — | — | — | — |
| 9. DM | M/39 | 9 | 78 | 15.62-153 | 1 | 1 | 4 | 4 | 10 |
| Mean ± SD | 36.2 ± 15.4 | 9.0 ± 4.4 | 118.4 | 10.3 | 2.2 | 1.3 | 3.2 | 2.0 | 8.7 |
| Range | 7-50 | 4-16 | 43-290 | .28-40.5 | 1-6 | 1-3 | 3-4 | 0-4 | 5-13 |
Average of the two earliest available values from 1995 to 1997.
All biopsies were performed within 1 year of HCV RNA assay with the exception of WF whose was done 2 years before HCV RNA testing.
BMT recipient.
Value determined by quantitative PCR-based monitor test (Roche Molecular Systems, Nutley, NJ) and multiplied by 4 (see text).